Search

Management of diabetic macular oedema in vitrectomised eyes

Diabetic macular oedema (DMO) is one of the leading causes of blindness; its prevalence is on the rise with progressive increase in numbers of people suffering from diabetes. The management of DMO has evolved significantly over the past few years....

Improved efficacy expected with second-generation microinvasive glaucoma surgery (MIGS) devices

Microinvasive surgical approaches to primary open-angle glaucoma (POAG) offer minimally traumatic options for effective intraocular pressure (IOP) reduction in appropriately selected glaucoma patients. Increases in laser trabeculoplasty rates and wider adoption of glaucoma drainage device filtration procedures, together with the...

Progress in retinal disease management: Highlights of the Retina Day, RCOphth 2025 Annual Congress

The Retina Day meeting at the Royal College of Ophthalmologists (RCOphth) 2025 Annual Congress in Liverpool was held on 22 May 2025. This report highlights 10 selected topics of interest to subspecialists and general ophthalmologists. Decarbonising anti-VEGF clinics (or making...

Well-presented scholarly research work will reduce chances of journal rebuttal

Submitting to an academic journal? Are you aware of the requirements and constraints of relevant copyright laws? Rod McNeil provides a guide for aspiring authors. Getting published in peer-reviewed academic and medical journals is not easy. But careful attention to...

Enter the Dragons’ Den: Bob Gokani

I have often daydreamed about inventing a successful new product and then going on to pitch for investment on Dragons’ Den, with the TV show’s seasoned entrepreneurs all competing with each other to invest in my company. My imagined fantasy...

Enter the Dragons’ Den: Bob Gokani

I have often daydreamed about inventing a successful new product and then going on to pitch for investment on Dragons’ Den, with the TV show’s seasoned entrepreneurs all competing with each other to invest in my company. My imagined fantasy...

Glaucoma-NET: a novel way of improving glaucoma management in sub-Saharan Africa

Background Glaucoma is the second most common cause of blindness worldwide [1]. People with untreated glaucoma suffer from irreversible, progressive loss of sight. The disease is characterised by progressive loss of visual field, with pathological cupping of the optic disc...

Corporate M&A pace gathers momentum

Intensifying franchise competition, maturing product development pipelines and looming loss of exclusivity spur renewed merger and acquisition (M&A) activity in the ophthalmics sector. Rod McNeil reviews recent deals and related strategic developments. AbbVie to acquire Allergan in $63 billion mega-combination,...

Real-world experience and outcomes of SLT laser used as a first-line treatment in ocular hypertension patients in a United Kingdom National Health Service setting

The management of raised intraocular pressure (IOP) in the context of ocular hypertension (OHT) and primary open angle glaucoma (POAG) remains a major contributor to the workload of ophthalmology units across the UK. Treatment of these conditions has historically centred...